File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy

TitleFactors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
Authors
Issue Date2001
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2001, v. 34 n. 4 I, p. 785-791 How to Cite?
AbstractFactors associated with hepatitis B virus (HBV) DNA breakthrough and the significance of YMDD variants without the presence of wild-type YMDD during prolonged lamb vudine treatment are unknown. We studied the amino acid sequence of codon 552 (YMDD motif) and codon 528 by means of a line probe assay in 159 chronic HBV patients (median follow-up 29.6 months). Pretreatment HBV DNA levels and alanine transaminase (ALT) levels correlated inversely with the time to HBV DNA breakthrough with YMDD variants (r=-0.46, P=.001; r=-0.45, P=.001 respectively). Patients harboring YMDD variants 3 months before HBV DNA breakthroughs had higher HBV DNA breakthrough levels compared with those without YMDD variants 3 months before HBV DNA breakthroughs (18.9×106 vs. 5.4×106 copies/mL, P=.007). Patients with HBV DNA breakthroughs had higher percentages of YMDD variants without the presence of wild-type YMDD compared with patients without HBV DNA breakthrough (25.6% vs. 9%, P=.007 for single M552I variant; 20.9% vs. 8.1%, P=.026 for single M552V variant; 30.2% vs. 9.9%, P=.004 for M552I/M552V variants). Patients with HBV DNA levels of more than 103 copies/mL after 6 months of lamivudine therapy had a 63.2% chance of subsequently developing YMDD variants. HBeAg seroconversion occurred in 2 patients after the emergence of YMDD variants. Only one patient developed YMDD variant after HBeAg seroconversion. There was no increase in the rate of development of YMDD variants or L528M mutation in patients receiving lamivudine 25 mg daily or famciclovir 500 mg 3 times a day before being given lamivudine 100 mg daily.
Persistent Identifierhttp://hdl.handle.net/10722/76460
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorSablon, Een_HK
dc.contributor.authorHui, CKen_HK
dc.contributor.authorYuan, HJen_HK
dc.contributor.authorDecraemer, Hen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:21:28Z-
dc.date.available2010-09-06T07:21:28Z-
dc.date.issued2001en_HK
dc.identifier.citationHepatology, 2001, v. 34 n. 4 I, p. 785-791en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76460-
dc.description.abstractFactors associated with hepatitis B virus (HBV) DNA breakthrough and the significance of YMDD variants without the presence of wild-type YMDD during prolonged lamb vudine treatment are unknown. We studied the amino acid sequence of codon 552 (YMDD motif) and codon 528 by means of a line probe assay in 159 chronic HBV patients (median follow-up 29.6 months). Pretreatment HBV DNA levels and alanine transaminase (ALT) levels correlated inversely with the time to HBV DNA breakthrough with YMDD variants (r=-0.46, P=.001; r=-0.45, P=.001 respectively). Patients harboring YMDD variants 3 months before HBV DNA breakthroughs had higher HBV DNA breakthrough levels compared with those without YMDD variants 3 months before HBV DNA breakthroughs (18.9×106 vs. 5.4×106 copies/mL, P=.007). Patients with HBV DNA breakthroughs had higher percentages of YMDD variants without the presence of wild-type YMDD compared with patients without HBV DNA breakthrough (25.6% vs. 9%, P=.007 for single M552I variant; 20.9% vs. 8.1%, P=.026 for single M552V variant; 30.2% vs. 9.9%, P=.004 for M552I/M552V variants). Patients with HBV DNA levels of more than 103 copies/mL after 6 months of lamivudine therapy had a 63.2% chance of subsequently developing YMDD variants. HBeAg seroconversion occurred in 2 patients after the emergence of YMDD variants. Only one patient developed YMDD variant after HBeAg seroconversion. There was no increase in the rate of development of YMDD variants or L528M mutation in patients receiving lamivudine 25 mg daily or famciclovir 500 mg 3 times a day before being given lamivudine 100 mg daily.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshDNA, Viral - analysis - metabolismen_HK
dc.subject.meshDNA-Directed DNA Polymerase - geneticsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis B e Antigens - analysisen_HK
dc.subject.meshHepatitis B virus - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMutationen_HK
dc.titleFactors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=34&issue=4 Pt 1&spage=785&epage=791&date=2001&atitle=Factors+associated+with+hepatitis+B+virus+DNA+breakthrough+in+patients+receiving+prolonged+lamivudine+therapy.en_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/jhep.2001.27563en_HK
dc.identifier.pmid11584376en_HK
dc.identifier.scopuseid_2-s2.0-0034802516en_HK
dc.identifier.hkuros66978en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034802516&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume34en_HK
dc.identifier.issue4 Ien_HK
dc.identifier.spage785en_HK
dc.identifier.epage791en_HK
dc.identifier.isiWOS:000171218500022-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridSablon, E=6603694538en_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridYuan, HJ=7402446707en_HK
dc.identifier.scopusauthoridDecraemer, H=6506949999en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats